breast

Audio Journal of Oncology Volume 16 Number 11+

3rd June 2008
Michael Gnant

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)

Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago

michael gnant Audio Journal of Oncology Volume 16 Number 11

Michael Gnant

In this edition:

1. Zoledronic …

Read More+

Audio Journal of Oncology Volume 16 Number 10+

25th May 2008
Myron Czuczman

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin

In this edition Peter Goodwin and Sara Freeman report from:
European Breast Cancer Conference, Berlin, April 15-19, 2008;
Chemotherapy …

Read More+

Audio Journal of Oncology Volume 16 Number 9+

26th April 2008
Angel Rodriguez

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam

angel rodriquez Audio Journal of Oncology Volume 16 Number 9

Angel Rodriguez

In this edition:

1. Lapatinib: Targets Breast Cancer Stem Cells?

Angel Rodriguez, Baylor College, Houston…

Read More+

Audio Journal of Oncology Volume 16 Number 8+

15th April 2008

Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna

In this edition:

Bevacizumab and Survival in Metastatic Breast Cancer

Source: N Engl J Med 357:26
George Canellos, Dana-Farber Cancer Institute, Boston
Progresson-free survival, but not overall survival, was …

Read More+

Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone+

1st February 2008
Cora Sternberg
cora sternberg Hormone Refractory Prostate Cancer: Increased Progression Free Survival With Satraplatin and Prednisone
Cora Sternberg
REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving

…

Read More+

London School of Hygiene & Tropical Medicine Audio News – Undernutrirtion Causes a Third of Child Deaths+

17th January 2008
Zulfiqar Bhutta
zulfiqar bhutta London School of Hygiene & Tropical Medicine Audio News Undernutrirtion Causes a Third of Child Deaths
Zulfiqar Bhutta

Reference: The Lancet, Maternal and Child Undernutrition Special Series
With one child in three killed by it, childhood and maternal undernutrition are discussed in a special series of articles in the Lancet. Sarah Maxwell spoke with Zulfiqar Bhutta

…

Read More+

Early Breast Cancer Chemotherapy: Long Term Findings+

8th January 2008
Richard Peto
richard peto Early Breast Cancer Chemotherapy: Long Term Findings
Richard Peto

REFERENCE: Lancet 371:29-40; January 5, 2008
RICHARD PETO, Oxford University
The prospect of cutting breast cancer mortality in half throughout the world is held out by Richard Peto of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). He

…

Read More+

ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up+

15th December 2007
Jack Cuzick
jack cuzick ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
Jack Cuzick

JACK CUZICK, Wolfson Institute of Preventive Medicine, London
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data

…

Read More+

New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer+

15th December 2007
Jose Baselga
jose baselga New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
Jose Baselga

JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and

…

Read More+

Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer+

16th November 2007
Jean-Yves Douillard
jean yves douillard Two New Second Line Options For Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Jean-Yves Douillard
gordon mcvie Two New Second Line Options For Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Gordon McVie

REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JEAN-YVES DOUILLARD, Centre René Gauducheau, Nante
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
The vinca alkaloid vinflunine and

…

Read More+

Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer+

2nd November 2007
Nicholas James
nicholas james Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer
Nicholas James
gordon mcvie Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer
Gordon McVie

REFERENCE: Abstract: 3LB (Presidential Session), ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
NICHOLAS JAMES, Birmingham University
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
A new drug has improved overall survival

…

Read More+

Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer+

16th October 2007
Jose Baselga
jose baselga Neoadjuvant Trastuzumab: Marked Benefit in HER2 Positive Inflammatory Breast Cancer
Jose Baselga
gordon mcvie Neoadjuvant Trastuzumab: Marked Benefit in HER2 Positive Inflammatory Breast Cancer
Gordon McVie

REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
Neoadjuvant trastuzumab for patients with HER2-positive

…

Read More+